September 25, 2024
Statement on the UN High Level Meeting on Antimicrobial Resistance Final Draft Political Declaration
Statement / Press
Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.
September 16, 2024
2024 Research in Action Awards Celebrate Leaders in Global Health Activism Who Exemplify TAG’s Mission
Statement / Press
Treatment Action Group’s (TAG) most important fundraising event of the year is the Research in Action Awards, which honor the best and brightest activists, researchers, leaders, and scientists whose work has been integral in ending HIV, tuberculosis (TB), and hepatitis C (HCV).
August 14, 2024
Treatment Action Group Calls for Coordinated, Fully Funded Global Response to Mpox Emergency
Statement / Press
Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.
July 25, 2024
Three New Members Elected to TAG’s Board of Directors
Statement / Press
Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, “TAG is reinvigorating its Board in alignment with our vision, mission, and values.
July 18, 2024
2024 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
July 17, 2024
2023 Annual Report
Publication
We’re pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.
June 26, 2024
Call For New Global TB CAB Members
On behalf of the Global Tuberculosis Community Advisory Board (TB CAB), we’re excited to announce a call for new member applications.
June 26, 2024
TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public
Statement / Press
Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.
June 20, 2024
An Open Letter to Médecins Sans Frontières — Urgent Call to Reverse the Devastating Decision to Shutter the MSF Access Campaign
Letter / Comment
TAG’s emergency plea to our allies at MSF to preserve its life-saving and world-changing MSF Access Campaign (Campaign for Access to Essential Medicines) — we need them now more than ever!
May 30, 2024
Comments Delivered at the WHO Director-General’s TB Vaccine Accelerator Council
Letter / Comment
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 2nd meeting of the WHO Director-General’s TB Vaccine Accelerator Council in Geneva Switzerland.
May 17, 2024
TAG Comments at UN High-Level Meeting on Antimicrobial Resistance Hearing
Letter / Comment
TAG delivered an intervention at the UN High-Level Meeting on Antimicrobial Resistance (AMR) Multistakeholder Hearing, calling on member states to incorporate drug-resistant TB (DR-TB) in the political declaration as a key component of AMR response.
May 15, 2024
TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
Webinar / Presentation
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
May 13, 2024
Comments In Regard to NIAID’S Strategic Plan, May 2024
Letter / Comment
Treatment Action Group submitted comments in response to “Request for Information (RFI): Inviting Comments and Suggestions on NIAID’s Strategic Plan” highlighting the organization’s key priorities across the NIAID portfolio.
May 10, 2024
An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP
Publication
Rifapentine, an off-patent drug that’s been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
May 10, 2024
Director of Development
Treatment Action Group (TAG) seeks a dynamic, motivated, and skilled individual to become its Director of Development supporting the organization as it continues to grow.